MORF-057 – A selective oral α4B7 Integrin Inhibitor for Inflammatory Bowel Disease

Time: 11:30 am
day: Day Two


  • α4B7 Integrin inhibition is a clinically validated mechanism of action to treat IBD
  • Utilizing the MInT platform, we have identified the highly selective oral Inhibitor MORF-057 and advanced it into clinical studies
  • Phase 1 clinical data support the initiation of Phase 2 clinical trials in UC